**Correction to:** *Signal Transduction and Targeted Therapy* 10.1038/s41392-019-0063-8, published online 23 August 2019

Since the publication of this Review Article, we noticed several mistakes in Table [2](#Tab1){ref-type="table"} and the Perspective section that need to be corrected immediately.Table 2Current status of selected AD drugs in clinical trialsDrugDeveloperMechanism of actionStageNCT number\
(https://clinicaltrials.gov)AAB-003(PF‑05236812)Janssen/PfizerAβ-specific mAbPhase I(completed)^457^NCT01193608GV-971Shanghai Green Valley Pharmaceutical Co., Ltd.Mannose oligosaccharide diacidPhase III(completed in China)NCT02293915

In Table [2](#Tab1){ref-type="table"}, the status of AAB-003 Phase I trial is completed. In addition, the status of GV-971 Phase III trial is completed in China. The correct portion of Table [2](#Tab1){ref-type="table"} is displayed as below.

In the perspective section, the sigma-1 receptor activator Anavex 2-73 has entered a phase III clinical trial but it was not granted fast-track status by the FDA. Therefore, the texts should be corrected to "In addition, fluoxetine can bind to the endoplasmic reticulum protein sigma-1 receptor.^418^ Sigma-1 receptor ligands can enhance acetylcholine secretion.^419,420^ The sigma-1 receptor is located in the mitochondrion-associated ER membrane so that the activation of the sigma-1 receptor can prolong Ca^2+^ signaling in mitochondria.^421^ Consequently, the local and specific elevation of \[Ca^2+^\] in the mitochondrial matrix can enhance ATP synthesis,^422,423^ which ameliorates hypometabolism. Interestingly, Anavex 2-73, a sigma-1 receptor activator is now in phase III clinical trial."

The key messages of the article are not affected by these corrections. We apologize for these inadvertent mistakes.
